Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 3
2014 5
2015 15
2016 13
2017 9
2018 17
2019 9
2020 22
2021 15
2022 9
2023 11
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade.
Gu SS, Zhang W, Wang X, Jiang P, Traugh N, Li Z, Meyer C, Stewig B, Xie Y, Bu X, Manos MP, Font-Tello A, Gjini E, Lako A, Lim K, Conway J, Tewari AK, Zeng Z, Sahu AD, Tokheim C, Weirather JL, Fu J, Zhang Y, Kroger B, Liang JH, Cejas P, Freeman GJ, Rodig S, Long HW, Gewurz BE, Hodi FS, Brown M, Liu XS. Gu SS, et al. Cancer Discov. 2021 Jun;11(6):1524-1541. doi: 10.1158/2159-8290.CD-20-0812. Epub 2021 Feb 15. Cancer Discov. 2021. PMID: 33589424 Free PMC article.
SIGNIFICANCE: MHC-I loss or downregulation in cancer cells is a major mechanism of resistance to T cell-based immunotherapies. Our study reveals that birinapant may be used for patients with low baseline MHC-I to enhance ICB response. This represents promising immunotherap …
SIGNIFICANCE: MHC-I loss or downregulation in cancer cells is a major mechanism of resistance to T cell-based immunotherapies. Our study rev …
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.
Vredevoogd DW, Kuilman T, Ligtenberg MA, Boshuizen J, Stecker KE, de Bruijn B, Krijgsman O, Huang X, Kenski JCN, Lacroix R, Mezzadra R, Gomez-Eerland R, Yildiz M, Dagidir I, Apriamashvili G, Zandhuis N, van der Noort V, Visser NL, Blank CU, Altelaar M, Schumacher TN, Peeper DS. Vredevoogd DW, et al. Cell. 2019 Jul 25;178(3):585-599.e15. doi: 10.1016/j.cell.2019.06.014. Epub 2019 Jul 11. Cell. 2019. PMID: 31303383 Free article.
Inhibition of cIAP1 in the effective suppression of chemotherapy‑resistant hepatoblastoma.
Tsukada R, Nomura M, Ueno T, Okuyama H. Tsukada R, et al. Oncol Rep. 2022 Apr;47(4):79. doi: 10.3892/or.2022.8290. Epub 2022 Feb 25. Oncol Rep. 2022. PMID: 35211761
Huh6 cells were exposed to CDDP and/or birinapant in order to confirm tumor growth inhibition. The antitumor efficacy of birinapant plus CDDP combination therapy was significantly higher than that of CDDP monotherapy in a dose-dependent manner (P=0.035). ...Compared …
Huh6 cells were exposed to CDDP and/or birinapant in order to confirm tumor growth inhibition. The antitumor efficacy of birinapan …
Birinapant Reshapes the Tumor Immunopeptidome and Enhances Antigen Presentation.
Zhang W, Sun S, Zhu W, Meng D, Hu W, Yang S, Gao M, Yao P, Wang Y, Wang Q, Ji J. Zhang W, et al. Int J Mol Sci. 2024 Mar 25;25(7):3660. doi: 10.3390/ijms25073660. Int J Mol Sci. 2024. PMID: 38612472 Free PMC article.
Birinapant, an antagonist of the inhibitor of apoptosis proteins, upregulates MHCs in tumor cells and displays a better tumoricidal effect when used in combination with immune checkpoint inhibitors, indicating that Birinapant may affect the antigen presentation path …
Birinapant, an antagonist of the inhibitor of apoptosis proteins, upregulates MHCs in tumor cells and displays a better tumoricidal e …
The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.
Zhou L, Zhang Y, Leng Y, Dai Y, Kmieciak M, Kramer L, Sharma K, Wang Y, Craun W, Grant S. Zhou L, et al. J Hematol Oncol. 2019 Mar 7;12(1):25. doi: 10.1186/s13045-019-0713-x. J Hematol Oncol. 2019. PMID: 30845975 Free PMC article.
Genetically modified cells (e.g., exhibiting shRNA knockdown or ectopic expression) were employed to evaluate the functional significance of birinapant/bortezomib-induced changes in protein levels. A MM xenograft model was used to evaluate the in vivo activity of the bi …
Genetically modified cells (e.g., exhibiting shRNA knockdown or ectopic expression) were employed to evaluate the functional significance of …
The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity.
Song EZ, Wang X, Philipson BI, Zhang Q, Thokala R, Zhang L, Assenmacher CA, Binder ZA, Ming GL, O'Rourke DM, Song H, Milone MC. Song EZ, et al. Mol Ther Oncolytics. 2022 Nov 15;27:288-304. doi: 10.1016/j.omto.2022.11.004. eCollection 2022 Dec 15. Mol Ther Oncolytics. 2022. PMID: 36458202 Free PMC article.
Therefore, birinapant could enhance CAR T cell-mediated bystander death of antigen-negative GBM cells, thus preventing tumor antigenic escape in antigen-heterogeneous tumor models in vitro and in vivo. In addition, birinapant could promote the activation of NF-kappa …
Therefore, birinapant could enhance CAR T cell-mediated bystander death of antigen-negative GBM cells, thus preventing tumor antigeni …
[Anti-hepatoma effects of Smac analogue Birinapant and its related molecular mechanism].
Jiang PR, Ke RJ, Zhu ML, Lou EZ, Xie JG, Chen JY. Jiang PR, et al. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2018 Jun 8;34(6):524-529. doi: 10.12047/j.cjap.5685.2018.117. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2018. PMID: 31032587 Free article. Chinese.
OBJECTIVE: To investigate the effects of Birinapant on hepatocellular carcinoma cells and its related molecular mechanisms. ...CONCLUSIONS: Birinapant can inhibit the expression of cIAP-1, cIAP-2 and the proteins of Ras-Raf-MEK-ERK signal pathways, so as to activate …
OBJECTIVE: To investigate the effects of Birinapant on hepatocellular carcinoma cells and its related molecular mechanisms. ...CONCLU …
The SMAC mimetic birinapant alleviates lipopolysaccharide-induced acute lung injury by inhibiting MAPK signaling.
Hu H, Ma M, Li T, Shi L, Li P. Hu H, et al. Immunol Lett. 2023 Dec;264:31-35. doi: 10.1016/j.imlet.2023.10.008. Epub 2023 Oct 31. Immunol Lett. 2023. PMID: 37913914
The present study was to investigate the effects of birinapant on ALI and its possible mechanism. A dose of birinapant (30 mg/kg) or a vehicle was administered intravenously 24 hours before LPS (100 mug) stimulation in mice. ...In addition, birinapant markedl …
The present study was to investigate the effects of birinapant on ALI and its possible mechanism. A dose of birinapant (30 mg/ …
SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway.
Ding J, Qin D, Zhang Y, Li Q, Li Y, Li J. Ding J, et al. Mol Med Rep. 2020 Mar;21(3):1251-1257. doi: 10.3892/mmr.2020.10908. Epub 2020 Jan 3. Mol Med Rep. 2020. PMID: 31922244 Free PMC article.
Birinapant also promoted apoptosis and inhibited the growth of subcutaneous hepatocellular carcinoma tumors in nude mice. ...The molecular mechanism responsible for the effects of birinapant may be related to activation of the cIAP1/TRAF3 signaling pathway by bir …
Birinapant also promoted apoptosis and inhibited the growth of subcutaneous hepatocellular carcinoma tumors in nude mice. ...The mole …
122 results